Sequitur, Procter and Gamble Pharmaceuticals to Collaborate on Target Validation Study | GenomeWeb

NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.

Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies. 

Financial details were not disclosed. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."